US20040171663A1 - Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives - Google Patents

Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives Download PDF

Info

Publication number
US20040171663A1
US20040171663A1 US10/784,232 US78423204A US2004171663A1 US 20040171663 A1 US20040171663 A1 US 20040171663A1 US 78423204 A US78423204 A US 78423204A US 2004171663 A1 US2004171663 A1 US 2004171663A1
Authority
US
United States
Prior art keywords
prophylaxis
treatment
diabetic
compound
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/784,232
Inventor
Yoshiharu Hayashi
Nobuharu Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/784,232 priority Critical patent/US20040171663A1/en
Publication of US20040171663A1 publication Critical patent/US20040171663A1/en
Priority to US11/152,376 priority patent/US20050239856A1/en
Priority to US11/363,202 priority patent/US20060148875A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present invention relates to an agent for the prophylaxes and treatment of diabetic complications, namely, to an agent for the prophylaxis and treatment of diabetic neuropathy, nephropathy, ophthalmopathy and arteriosclerosis. More particularly, the present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications.
  • the therapy of diabetes aims at prevention of such chronic complications, and practically consists of a further control of blood glucose and a direct therapy of complications.
  • the major chronic complications of diabetes are known to be neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like (David M. et al., N. Engl. J. Med., 328, p.1676-1685(1993)).
  • TX thiromboxane
  • lipoprostaglandin E1 (hereinafter sometimes to be referred to as Lipo PGE 1) having peripheral circulation improving action or platelet aggregation inhibitory action, 6-[4-(1 cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyryl(cilostazol) and 6-[4-(R)-chlorophenylsulfonamido]-1-(3-pyridylmethyl)pyrrolidin-2(S)-yl)-5-(Z)-hexenoic acid•hydrochloride (investigational number: KDI-792) having TXA2 receptor antagonistic/synthesis inhibitory activity have been under development as agents for the prophylaxis and treatment of diabetic complications.
  • Lipo PGE 1 having peripheral circulation improving action or platelet aggregation inhibitory action, 6-[4-(1 cyclohexyl-1,2,3,4-tetrazol-5-yl)but
  • Japanese Patent Examined Publication No. 41143/1993 discloses 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid having pharmacological activities such as strong TXA2 biosynthesis inhibitory activity, platelet aggregation inhibitory action, vasodilating action and the like, which is useful for the prophylaxis and treatment of thrombosis, cerebral hemorrhage, myocardial infarction, acute cardiac death, angina pectoris, hypertension, asthma, naphrtis and the like, an optically active compound and a pharmaceutically acceptable salt thereof. Nevertheless, it is not known that these compounds act as agents for the prophylaxis and treatment of diabetic complications.
  • Lipo PGE 1, cilostazol, KDI-792 and the like which are under development as agents for the prophylaxis and treatment of diabetic complications based on the above-mentioned peripheral circulation improving activity, platelet aggregation inhibitory activity and TXA2 receptor antagonistic/synthesis inhibitory activity, all exhibit only a short duration of activity and require 2 to 3 times of administration a day. Considering the quality of life of the patients with diabetes, they are remotely sufficient.
  • the present inventors have confirmed that sodium ozagrel [sodium (E)-p-(imidazol-1-ylmethyl)cinnamate] having TXA2 synthesis inhibitory activity suppresses promotion of biosynthesis of TXA2 in rats with diabetes, but does not improve decreased tail nerve conduction velocity. This suggests that not every TXA2 synthesis inhibitor is effective for diabetic complications.
  • the present inventors have conducted intensive studies from this viewpoint and found that 4-[ ⁇ -hydroxy-2-methyl-5-(1-imdazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof and a pharmaceutically acceptable salt thereof, having pharmacological activities of TXA2 biosynthesis inhibitory activity, platelet aggregation inhibitory activity and vasodilating action, are useful for the prophylaxis and treatment of diabetic complications, namely, for the prophylaxis and treatment of diabetic neuropathy, nephropathy, opthalmopathy and arteriosclerosis, and that the activity thereof is long-lasting for small doses, thus enabling a single administration a day, which resulted in the completion of the present invention.
  • the present invention provides the following
  • An agent for the prophylaxis and treatment of diabetic complications comprising 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid, an optically active compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • An agent for the prophylaxis and treatment of diabetic complications comprising (S)-( ⁇ )-4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
  • An agent for the prophylaxis and treatment of diabetic complications comprising sodium (S)-( ⁇ )4[ ⁇ -hydroxy-2-methyl- 5 (1-imidazolyl)benzyl]-3,5 dimethylbenzoate 2 ⁇ 3 hydrate as an active ingredient.
  • a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.
  • diabetic complication is at least one member selected from the group consisting of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis.
  • diabetic complication is at least one member selected from the group consisting of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis.
  • a pharmaceutical composition for the prophylaxis and treatment of diabetic complications which comprises an effective amount of 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for the prophylaxis and treatment of diabetic complications which comprises an effective amount of sodium 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for the prophylaxis and treatment of diabetic complications which comprises an effective amount of (S)-( ⁇ )-4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for the prophylaxis and treatment of diabetic complications which comprises an effective amount of sodium (S)-( ⁇ )-4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate 2 ⁇ 3 hydrate and a pharmaceutically acceptable carrier.
  • a commercial package comprising the pharmaceutical composition of any one of the above 28) to 31) and a written matter associated therewith, the written matter stating that said pharmaceutical composition can or should be used for the prophylaxis and treatment of diabetic complications.
  • the action as the agent for the prophylaxis and treatment of diabetic complications of the present invention namely, the action as the agent for the prophylaxis and treatment of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis, can be confirmed through rat tail nerve conduction velocity, sciatic nerve conduction velocity, degree of glomerular disorder, amount of urinary albumin excretion, degree of cataract examining funduscopy, degree of hypertrophy and the like.
  • neuropathy means symmetric polyneuropathy of sensory, motor and autonomic nerves, and local or polydomous neuropathy of cerebral nerve; and ophthalmopathy means cataract, glaucoma, retinopathy, ulceris and the like.
  • the compounds of the present invention can be synthesized by the methods described in Japanese Patent Examined Publication No. 41143/1993 and Japanese Patent Unexamined Publication No. 215771/1990.
  • the pharmaceutically acceptable salts of the compounds of the present invention include, for example, salts with inorganic acid such as hydrochloric acid, hydrobromic acid and sulfuric acid; acid addition salts with organic acid such as fumaric acid, maleic acid, mandelic acid, citric acid, tartaric acid, salicylic acid and the like; salts with metal such as sodium, potassium, lithium, calcium, magnesium, zinc and aluminum and salts with amino acid such as lysine.
  • hydrates such as 1 ⁇ 2 hydrate, 1 ⁇ 3 hydrate, 2 ⁇ 3 hydrate, monohydrate, ⁇ fraction (3/2) ⁇ hydrate and dihydrate, are also encompassed.
  • Preferable compounds of the present invention include sodium 4-[ ⁇ -hydroxy-2-methyl-5-(1-imidazoly)benzyl]-3,5-dimethylbenzoate dihydrate (hereinafter sometimes referred to as compound A-1), sodium (S)-( ⁇ )-4[ ⁇ -hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate 2 ⁇ 3 hydrate (hereinafter sometimes referred to as compound A- 2 ), sodium (R)-(+)-4-[ ⁇ -hydroxy-2-methyl-5-(1-dazolyl)benzyl]-3,5-dimethylbenzoate 2 ⁇ 3 hydrate (hereinafter sometimes referred to as compound A-3), (S)-( ⁇ )-4-[ ⁇ -hydroxy-2-methyl-5-(1-dazolyl)benzyl]-3,5-dimethylbenzoic acid (hereinafter sometimes referred to as compound A4), and (R)-(+)4-[ ⁇ -hydroxy-2-methyl-5-(
  • Compound A-1 is crystals having a melting point of 271-285° C.
  • the agent for the prophylaxis and treatment of diabetic complications according to the present invention is formulated as a general pharmaceutical preparation.
  • the compound of the present invention is formulated into a dosage form suitable for oral or parenteral administration; such as a pharmaceutical composition or tablet, pill, powder, granule, capsule, troche, syrup, liquid, emulsion, suspension, injection (liquid, suspension), suppository, inhalant, percutaneous absorber, eye drop, eye ointment and the like, which is produced by admixing the compound with a pharmaceutically acceptable carrier (e.g., excipient, binder, disintegrator, corrective, corrigent, emulsifier, diluent, solubilizer and the like).
  • a pharmaceutically acceptable carrier e.g., excipient, binder, disintegrator, corrective, corrigent, emulsifier, diluent, solubilizer and the like.
  • an additive such as sucrose, lactose, cellulose, D-mannitol, maltitol, dextran, starch, agar, arginates, chitins, chitosans, pectin, tragacanth gums, gum arabic, gelatins, collagens, casein, albumin, calcium phosphate, sorbitol, glycine, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, glycerol, polyethylene glycol, sodium hydrogencarbonate, magnesium stearate, talc and the Luke.
  • tablets are prepared to have an ordinary tablet coating to give, for example, sugar-coated tablet, enteric-coated tablet, film-coated tablet or two layer tablet or multi-layer tablet.
  • animal and plant fats and oils e.g., olive oil, corn oil, castor oil and the like
  • mineral oil and fats e.g., petrolatum, white petrolatum, solid paraffin and the like
  • wax e.g., jojoba oil, carnauba wax, yellow bees wax and the like
  • partially synthesized or entirely synthesized glycerol fatty acid ester e.g., lauric acid ester, myristic acid ester, palmitic acid ester and the like
  • examples of commercially available products thereof include Witepsol (manufactured by Dynamite Novel), Pharmasol (manufactured by NOF Corporation) and the like.
  • an additive such as sodium chloride, sorbitol, glycerol, olive oil, propylene glycol, ethyl alcohol and the like is used.
  • a sterile aqueous solution e.g., physiological saline and isotonic solution
  • oily liquid e.g., sesame oil and soy bean oil
  • an adequate suspending agent e.g., sodium carboxymethylcellulose
  • non-ionic surfactant e.g., benzyl benzoate and benzyl alcohol
  • solubilizer e.g., benzyl benzoate and benzyl alcohol
  • an aqueous liquid or aqueous solution is used, which is particularly a sterile aqueous solution for injection.
  • This eye drop liquid may contain various additives as appropriate, such as buffer (preferably, borate buffer, acetate buffer, carbonate buffer and the like are used for reducing irritation), isotonizing agent, solubilizer, preservative, thickener, chelating agent, pH adjusting agent (preferably, pH is generally adjusted to about 6-8.5), aromatic and the like.
  • the amount of the active ingredient of these preparation is 0.1-100 wt %, suitably 1-50%, of the preparation.
  • the dose varies depending on the symptom, body weight, age and the like of patients. In the case of oral administration, the dose is generally about 0.01-50 mg/kg body weight/day for an adult, which is preferably administered in a single dose or several doses.
  • Diabetes was induced by intravenous administration of streptozotocin (65 mg/kg) to 6 week-old male Sprague-Dawley rats. Starting from 2-4 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing the compound of the present invention was orally administered once a day. At 4-7 weeks from the administration, tail nerve conduction velocity was measured with an induction potential test device (Neuropack 2, manufactured by Nihon Kohden) according to a modification of the method of Miyoshi (Fukuoka Medical Journal, vol. 62, pp. 588-603 (1971)). To be specific, subcutaneous temperature at the tail was maintained at 37° C.
  • TXB2 which is a stable metabolite of TXA2
  • the compound A-1 of the present invention decreased urinary TXB2 excretion that had been increased by diabetes, and increased tail nerve conduction velocity which had been decreased by diabetes, in a dose-dependent manner without affecting the blood glucose.
  • a 0.5% hydroxypropylmethylcellulose suspension containing the compound of the present invention was orally administered to 9-week-old male spontaneously diabetic mice (db/db) once a day.
  • sciatic nerve conduction velocity was measured with an induction potential test device (neuropack 2, manufactured by Nihon Kohden) according to a modification of the method of Yasuda (Diabetes, 38, p. 832-838 (1989)).
  • induction potential test device neuropack 2, manufactured by Nihon Kohden
  • rectal temperature was maintained at 37° C. and two points of sciatic notch and ankle were percutaneously stimulated electrically. The distance between the stimulation points was divided by the difference between latencies in induced electromyogram to give nerve conduction velocity.
  • the compound A-2 and compound A4 of the present invention increased sciatic nerve conduction velocity of spontaneous diabetic mice.
  • Diabetes was induced by intravenous administration of streptozotocin (65 mg/kg) to 6 week-old male Sprague-Dawley rats. Starting from 16 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing compound A-1 was orally administered once a day. At 5 weeks from the administration, tail nerve conduction velocity was measured with an induction potential test device (Neuropack 2, manufactured by Nihon Kohden) according to a modification of the method of Miyoshi (Fukuoka Medical Journal, vol. 62, pp. 588-603 (1971)). To be specific, subcutaneous temperature at the tail vas maintained at 37° C.
  • Diabetes was induced by intravenous administration of streptozotocin (65 mg/k, to 5-week-old male Sprague-Dawley rats. Starting from 9 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing compound A-1 was orally administered once a day. At 9 weeks from the administration, kidney was removed to determine the degree of glomerular disorder and fixed in a 10% neutral-buffered formalin solution Tissue sections were stained with hematoxylin/eosin. Glomerulus was evaluated according to the degree of obstruction in 5 stages (0: no obstruction, 1: up to 25% obstruction, 2: up to 50% obstruction, 3: up to 75% obstruction, 4: up to 100% obstruction).
  • the compound A-1 of the present invention suppressed glomerular disorder due to diabetes in a dose-dependent manner.
  • Diabetes is induced by intravenous administration of streptozotocin (65 mg/kg) to 6 week old male Sprague-Dawley rats. Starting from 2 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing compound A-1 is orally administered once a day. Urine is taken with the passage of time for 24 hours at several weeks' interval. The amount of urinary albumin excretion is determined by enzyme immunoassay. In addition, retina is photographed and examined by counting neogenetic blood vessels. After the completion of the drug administration, the rats are killed and blood vessels, such as aorta, are taken to make tissue samples. The sample stained with hematoxylin/eosin is observed with an optical microscope to quantitatively determine the degree of tunica intima.
  • the pharmaceutical agent of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like.
  • diabetic complications namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like.
  • the action of the drug is long-lasting for very small doses and a single administration a day is sufficient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of this compound. The medicament of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient.

Description

  • This is a divisional of Ser. No. 09/091,993, filed Jun. 26, 1998, which is a 371 of PCT/JP96/03776, filed December 24, 1996.[0001]
    • TECHNICAL FIELD
  • The present invention relates to an agent for the prophylaxes and treatment of diabetic complications, namely, to an agent for the prophylaxis and treatment of diabetic neuropathy, nephropathy, ophthalmopathy and arteriosclerosis. More particularly, the present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications. [0002]
    • BACKGROUND ART
  • The discovery of insulin and its clinical application resulted in drastic progress in the treatment of diabetes. Life sustention of the patients with diabetes—which had been a deadly disease until then—was strikingly improved. However, the therapy of chronic complications of diabetes has become a new problem. [0003]
  • The therapy of diabetes aims at prevention of such chronic complications, and practically consists of a further control of blood glucose and a direct therapy of complications. The major chronic complications of diabetes are known to be neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like (David M. et al., N. Engl. J. Med., 328, p.1676-1685(1993)). [0004]
  • Various factors have been considered to be responsible for the onset and progression of chronic complications of diabetes. For example, there are known an abnormal sorbitol metabolism theory wherein activity promotion of sorbitol-producing polyol metabolitic pathway is the cause (Gabbay K. H. et al., N. Engl. J. Med. 288, p.831-837(1973)), a circulatory disorder theory wherein causative factor is a decreased blood flow due to angiopathy (Dyck P. J. et. al., Proc. Natl. Acad. Sci. USA, 82, p.2513-2517 (1985)), a theory attributing the disease to a compound produced by non-enzymatic binding reaction of protein and reducing glucose (AGE:advanced glycation endproduct) (Brownlee M. et al., N. Engl. J. Med. 318, p.1315-1321 (1988)) and the like. Based on each hypothesis, an aldose reductase inhibitor and lipoprostaglandin E1 have been developed, and an AGE production inhibitor is under development. [0005]
  • The diabetic patients show promoted platelet aggregation, and the mechanism thereof has been known to be the promotion of biosynthesis of thiromboxane (hereinafter abbreviated as TX) A2 due to hyperglycemia. This is considered to be one of the pathogens of diabetic chronic complications (Giovanni Davi M. D. et al., N. Engl. J. Med. 322, p.1769-1774 (1990)). Thus, lipoprostaglandin E1 (hereinafter sometimes to be referred to as Lipo PGE 1) having peripheral circulation improving action or platelet aggregation inhibitory action, 6-[4-(1 cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyryl(cilostazol) and 6-[4-(R)-chlorophenylsulfonamido]-1-(3-pyridylmethyl)pyrrolidin-2(S)-yl)-5-(Z)-hexenoic acid•hydrochloride (investigational number: KDI-792) having TXA2 receptor antagonistic/synthesis inhibitory activity have been under development as agents for the prophylaxis and treatment of diabetic complications. [0006]
  • On the other hand, Japanese Patent Examined Publication No. 41143/1993 discloses 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid having pharmacological activities such as strong TXA2 biosynthesis inhibitory activity, platelet aggregation inhibitory action, vasodilating action and the like, which is useful for the prophylaxis and treatment of thrombosis, cerebral hemorrhage, myocardial infarction, acute cardiac death, angina pectoris, hypertension, asthma, naphrtis and the like, an optically active compound and a pharmaceutically acceptable salt thereof. Nevertheless, it is not known that these compounds act as agents for the prophylaxis and treatment of diabetic complications. [0007]
  • Under the circumstances, the development of a new therapeutic agent that acts directly on chronic complications of diabetes for the prophylaxis and treatment of diabetes, which is capable of providing a better quality of life has been desired. [0008]
  • The Lipo PGE 1, cilostazol, KDI-792 and the like, which are under development as agents for the prophylaxis and treatment of diabetic complications based on the above-mentioned peripheral circulation improving activity, platelet aggregation inhibitory activity and TXA2 receptor antagonistic/synthesis inhibitory activity, all exhibit only a short duration of activity and require 2 to 3 times of administration a day. Considering the quality of life of the patients with diabetes, they are remotely sufficient. [0009]
  • The present inventors have confirmed that sodium ozagrel [sodium (E)-p-(imidazol-1-ylmethyl)cinnamate] having TXA2 synthesis inhibitory activity suppresses promotion of biosynthesis of TXA2 in rats with diabetes, but does not improve decreased tail nerve conduction velocity. This suggests that not every TXA2 synthesis inhibitor is effective for diabetic complications. [0010]
    • DISCLOSURE OF THE INVENTION
  • The present inventors have conducted intensive studies from this viewpoint and found that 4-[α-hydroxy-2-methyl-5-(1-imdazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof and a pharmaceutically acceptable salt thereof, having pharmacological activities of TXA2 biosynthesis inhibitory activity, platelet aggregation inhibitory activity and vasodilating action, are useful for the prophylaxis and treatment of diabetic complications, namely, for the prophylaxis and treatment of diabetic neuropathy, nephropathy, opthalmopathy and arteriosclerosis, and that the activity thereof is long-lasting for small doses, thus enabling a single administration a day, which resulted in the completion of the present invention. [0011]
  • Accordingly, the present invention provides the following [0012]
  • 1) An agent for the prophylaxis and treatment of diabetic complications, comprising 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid, an optically active compound or a pharmaceutically acceptable salt thereof as an active ingredient. [0013]
  • 2) An agent for the prophylaxis and treatment of diabetic complications, comprising sodium 4-[α-hydroxy-2-methyl-5-(1-imidazoly)benzyl]-3,5 dimethylbenzoate dihydrate as an active ingredient. [0014]
  • 3) An agent for the prophylaxis and treatment of diabetic complications, comprising (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid or a pharmaceutically acceptable salt thereof as an active ingredient. [0015]
  • 4) An agent for the prophylaxis and treatment of diabetic complications, comprising sodium (S)-(−)4[α-hydroxy-2-methyl-[0016] 5(1-imidazolyl)benzyl]-3,5 dimethylbenzoate ⅔ hydrate as an active ingredient.
  • [0017] 5) The agent for the prophylaxis and treatment of the above 1) to 4), wherein the diabetic complication is at least one member selected from the group consisting of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis.
  • 6) The agent for the prophylaxis and treatment of the above 1) to 4), wherein the diabetic complication is neuropathy. [0018]
  • 7) The agent for the prophylaxis and treatment of the above 1) to 4), wherein the diabetic complication is nephropathy. [0019]
  • 8) The agent for the prophylaxis and treatment of the above 1) to 4), wherein the diabetic complication is ophthalmopathy. [0020]
  • 9) The agent for the prophylaxis and treatment of the above 1) to 4), wherein the diabetic complication is arteriosclerosis. [0021]
  • 10) A method for the prophylaxis and treatment of diabetic complications, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. [0022]
  • 11) A method for the prophylaxis and treatment of diabetic complications, comprising administering an effective amount of sodium 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate. [0023]
  • 12) A method for the prophylaxis and treatment of diabetic complications, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof. [0024]
  • 13) A method for the prophylaxis and treatment of diabetic complications, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate. [0025]
  • 14) The method of any one of the above 10) to 13) wherein the diabetic complication is at least one member selected from the group consisting of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis. [0026]
  • 15) The method of any one of the above 10) to 13) wherein the diabetic complication is neuropathy. [0027]
  • 16) The method of any one of the above 10) to 13) wherein the diabetic complication is nephropathy. [0028]
  • 17) The method of any one of the above 10) to 13) wherein the diabetic complication is ophthalmopathy. [0029]
  • 18) The method of any one of the above 10) to 13) wherein the diabetic complication is arteriosclerosis. [0030]
  • 19) Use of 4-[α-hydroxy-2-methyl-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof for the production of a medicament for the prophylaxis and treatment of diabetic complications. [0031]
  • 20) Use of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate for the production of a medicament for the prophylaxis and treatment of diabetic complications. [0032]
  • 21) Use of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid or a pharmaceutically acceptable salt thereof for the production of a medicament for the production of a medicament for the prophylaxis and treatment of diabetic complications. [0033]
  • 22) Use of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate for the production of a medicament for the prophylaxis and treatment of diabetic complications. [0034]
  • 23) The use of any one of the above 19) to 22) wherein the diabetic complication is at least one member selected from the group consisting of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis. [0035]
  • 24) The use of any one of the above 19) to 22) wherein the diabetic complication is neuropathy. [0036]
  • 25) The use of any one of the above 19) to 22) wherein the diabetic complication is nephropathy. [0037]
  • 26) The use of any one of the above 19) to 22) wherein the diabetic complication is ophthalmopathy. [0038]
  • 27) The use of any one of the above 19) to 22) wherein the diabetic complication is arteriosclerosis. [0039]
  • 28) A pharmaceutical composition for the prophylaxis and treatment of diabetic complications, which comprises an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [0040]
  • 29) A pharmaceutical composition for the prophylaxis and treatment of diabetic complications, which comprises an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate and a pharmaceutically acceptable carrier. [0041]
  • 30) A pharmaceutical composition for the prophylaxis and treatment of diabetic complications, which comprises an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5 dimethylbenzoic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [0042]
  • 31) A pharmaceutical composition for the prophylaxis and treatment of diabetic complications, which comprises an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate and a pharmaceutically acceptable carrier. [0043]
  • [0044] 32) The pharmaceutical composition of any one of the above 28) to 31) wherein the diabetic complication is at least one member selected from the group consisting of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis.
  • 33) The pharmaceutical composition of any one of the above 28) to 31) wherein the diabetic complication is neuropathy. [0045]
  • 34) The pharmaceutical composition of any one of the above 28) to 31) wherein the diabetic complication is nephropathy. [0046]
  • 35) The pharmaceutical composition of any one of the above 28) to 31) wherein the diabetic complication is ophthalmopathy. [0047]
  • 36) The pharmaceutical composition of any one of the above 28) to 31) wherein the diabetic complication is arteriosclerosis. [0048]
  • 37) A commercial package comprising the pharmaceutical composition of any one of the above 28) to 31) and a written matter associated therewith, the written matter stating that said pharmaceutical composition can or should be used for the prophylaxis and treatment of diabetic complications.[0049]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The action as the agent for the prophylaxis and treatment of diabetic complications of the present invention, namely, the action as the agent for the prophylaxis and treatment of neuropathy, nephropathy, ophthalmopathy and arteriosclerosis, can be confirmed through rat tail nerve conduction velocity, sciatic nerve conduction velocity, degree of glomerular disorder, amount of urinary albumin excretion, degree of cataract examining funduscopy, degree of hypertrophy and the like. [0050]
  • Of the diabetic complications in the present invention, neuropathy means symmetric polyneuropathy of sensory, motor and autonomic nerves, and local or polydomous neuropathy of cerebral nerve; and ophthalmopathy means cataract, glaucoma, retinopathy, iritis and the like. [0051]
  • The compounds of the present invention can be synthesized by the methods described in Japanese Patent Examined Publication No. 41143/1993 and Japanese Patent Unexamined Publication No. 215771/1990. [0052]
  • The pharmaceutically acceptable salts of the compounds of the present invention include, for example, salts with inorganic acid such as hydrochloric acid, hydrobromic acid and sulfuric acid; acid addition salts with organic acid such as fumaric acid, maleic acid, mandelic acid, citric acid, tartaric acid, salicylic acid and the like; salts with metal such as sodium, potassium, lithium, calcium, magnesium, zinc and aluminum and salts with amino acid such as lysine. Further, hydrates, such as ½ hydrate, ⅓ hydrate, ⅔ hydrate, monohydrate, {fraction (3/2)} hydrate and dihydrate, are also encompassed. [0053]
  • Preferable compounds of the present invention include sodium 4-[α-hydroxy-2-methyl-5-(1-imidazoly)benzyl]-3,5-dimethylbenzoate dihydrate (hereinafter sometimes referred to as compound A-1), sodium (S)-(−)-4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate (hereinafter sometimes referred to as compound A-[0054] 2), sodium (R)-(+)-4-[α-hydroxy-2-methyl-5-(1-dazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate (hereinafter sometimes referred to as compound A-3), (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-dazolyl)benzyl]-3,5-dimethylbenzoic acid (hereinafter sometimes referred to as compound A4), and (R)-(+)4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid (hereinafter sometimes referred to as compound A-5). Compound A-1 is crystals having a melting point of 271-285° C. Compound A-2 has an optical rotation of [α]D 23.5−149.50 (c=1.0, water), an optical rotation of compound A-3 is [α]D 24÷147.2° (c=1.0, water) and compound A4 has a melting point of 286-288° C. (decomposition) and an optical rotation of [α]D 21−261.5° (c=1.0, dimethylformamide), and compound A-S has a melting point of 286-287° C. (decomposition) and an optical rotation of [α]D 21+260.5° (c=1.0, dimethylformamide).
  • The agent for the prophylaxis and treatment of diabetic complications according to the present invention is formulated as a general pharmaceutical preparation. For example, the compound of the present invention is formulated into a dosage form suitable for oral or parenteral administration; such as a pharmaceutical composition or tablet, pill, powder, granule, capsule, troche, syrup, liquid, emulsion, suspension, injection (liquid, suspension), suppository, inhalant, percutaneous absorber, eye drop, eye ointment and the like, which is produced by admixing the compound with a pharmaceutically acceptable carrier (e.g., excipient, binder, disintegrator, corrective, corrigent, emulsifier, diluent, solubilizer and the like). When a solid preparation is prepared, an additive is used, such as sucrose, lactose, cellulose, D-mannitol, maltitol, dextran, starch, agar, arginates, chitins, chitosans, pectin, tragacanth gums, gum arabic, gelatins, collagens, casein, albumin, calcium phosphate, sorbitol, glycine, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, glycerol, polyethylene glycol, sodium hydrogencarbonate, magnesium stearate, talc and the Luke. Where necessary, tablets are prepared to have an ordinary tablet coating to give, for example, sugar-coated tablet, enteric-coated tablet, film-coated tablet or two layer tablet or multi-layer tablet. [0055]
  • When a semi-solid preparation is to be produced, animal and plant fats and oils (e.g., olive oil, corn oil, castor oil and the like), mineral oil and fats (e.g., petrolatum, white petrolatum, solid paraffin and the like), wax (e.g., jojoba oil, carnauba wax, yellow bees wax and the like), partially synthesized or entirely synthesized glycerol fatty acid ester (e.g., lauric acid ester, myristic acid ester, palmitic acid ester and the like) and the like are used. Examples of commercially available products thereof include Witepsol (manufactured by Dynamite Novel), Pharmasol (manufactured by NOF Corporation) and the like. [0056]
  • When a liquid preparation is to be produced, an additive such as sodium chloride, sorbitol, glycerol, olive oil, propylene glycol, ethyl alcohol and the like is used. Particularly when an injection is to be produced, a sterile aqueous solution (e.g., physiological saline and isotonic solution) or oily liquid (e.g., sesame oil and soy bean oil) is used. Where necessary, an adequate suspending agent (e.g., sodium carboxymethylcellulose), non-ionic surfactant, solubilizer (e.g., benzyl benzoate and benzyl alcohol) and the like may be also used. When an eye drop is to be produced, an aqueous liquid or aqueous solution is used, which is particularly a sterile aqueous solution for injection. This eye drop liquid may contain various additives as appropriate, such as buffer (preferably, borate buffer, acetate buffer, carbonate buffer and the like are used for reducing irritation), isotonizing agent, solubilizer, preservative, thickener, chelating agent, pH adjusting agent (preferably, pH is generally adjusted to about 6-8.5), aromatic and the like. [0057]
  • The amount of the active ingredient of these preparation is 0.1-100 wt %, suitably 1-50%, of the preparation. The dose varies depending on the symptom, body weight, age and the like of patients. In the case of oral administration, the dose is generally about 0.01-50 mg/kg body weight/day for an adult, which is preferably administered in a single dose or several doses. [0058]
    • EXAMPLES
  • The agent for the prophylaxis and treatment of diabetic complications of the present invention is explained more specifically by way of Formulation Examples and pharmacological activity. It should be noted that the present invention is not limited to these exemplifications. [0059]
    • Formulation Example 1 Film-Coated Tablet
  • [0060]
    Compound A-1 50.0 mg
    D-mannitol 70.5 mg
    Corn starch 16.0 mg
    Sodium hydrogencarbonate 15.0 mg
    Hydroxypropylmethylcellulose  3.0 mg
    Talc  5.0 mg
    Magnesium stearate  0.5 mg
  • Compound A-1, D-mannitol, corn starch and sodium hydrogencarbonate were mixed and an aqueous solution of hydroxypropylmethylcellulose was sprayed for flow granulation. The granules were passed through a 24-mesh sieve, and talc and magnesium stearate were added. The mixture vas processed in a rotary compressor (Kikusu Seisakusho) to give tablets each weighing 160 mg. Then, a film coating agent comprising hydroxypropylmethylcellulose as a film coating base was applied at 6 mg per tablet. [0061]
    • Formulation Example 2 Fine Granules
  • [0062]
    Compound A-1   10%
    D-mannitol 89.5%
    Hydroxypropylcellulose  0.5%
  • Compound A-1 and D-mannitol were mixed and an aqueous solution of hydroxypropylcellulose was added. The mixture was kneaded, which was followed by granulation and drying at 50° C. The granules were passed through a 32-mesh sieve to give fine granules. [0063]
    • Formulation Example 3 Tablets
  • [0064]
    Compound A-1 50.0 mg
    D-mannitol 30.0 mg
    Corn starch 19.0 mg
    Sodium hydrogencarbonate 15.0 mg
    Hydroxypropylmethylcellulose  1.5 mg
    Talc  4.0 mg
    Magnesium stearate  0.5 mg
  • Compound A-1, D-mannitol, corn starch and sodium hydrogencarbonate were mixed and an aqueous solution of hydroxypropylmethylceullulose was sprayed for flow granulation. The granules were passed through a 24-mesh sieve, and talc and magnesium stearate were added. The mixture was processed in a rotary compressor (Kikusui Seisakusho) to give tablets each weighing 120 mg. [0065]
    • Formulation Example 4 Fine Granules
  • [0066]
    Compound A-2  5%
    D-mannitol 92%
    Hydroxymethylpropylcellulose  3%
  • Compound A-2 and D-mannitol were mixed and an aqueous solution of hydroxypropylmethylcellulose was added. The mixture was kneaded, which was followed by granulation and drying at 50° C. The granules were passed through a 32-mesh sieve to give fine granules. [0067]
  • The pharmacological activity of the pharmaceutical agent of the present invention is explained by way of Experimental Examples. [0068]
    • Experimental Example 1
  • Diabetes was induced by intravenous administration of streptozotocin (65 mg/kg) to 6 week-old male Sprague-Dawley rats. Starting from 2-4 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing the compound of the present invention was orally administered once a day. At 4-7 weeks from the administration, tail nerve conduction velocity was measured with an induction potential test device (Neuropack 2, manufactured by Nihon Kohden) according to a modification of the method of Miyoshi (Fukuoka Medical Journal, vol. 62, pp. 588-603 (1971)). To be specific, subcutaneous temperature at the tail was maintained at 37° C. and the tail nerve was percutaneously stimulated electrically at 2 stimulation points (interval 6 cm). The distance between stimulation points was divided by the difference between latencies in electromyogram induced to give nerve conduction velocity. As to the test group in Table 1, blood glucose was measured at 6 weeks after administration. At 7 weeks after administration, urinary excretion of TXB2, which is a stable metabolite of TXA2, was measured. [0069]
    TABLE 1
    urinary TXB2 tail nerve conduction
    excretion velocity m/sec
    dose blood glucose ng/day/100 g 7 wks after
    test group mg/kg/day mg/dl body weight administration
    Control group 0 122.0 ± 3.8**  4.1 ± 0.4** 44.6 ± 0.5**
    Diabetes group 0 870.3 ± 78.5 16.9 ± 1.7 41.3 ± 0.5
    Compound A-1
    Administered group 0.03 718.3 ± 50.7 10.6 ± 1.4** 42.0 ± 0.5
    Compound A-1
    Administered group 0.1 772.1 ± 32.4  6.9 ± 0.8** 43.4 ± 0.4**
    Compound A-1
    Administered group 0.3 791.9 ± 65.5  5.1 ± 0.5** 43.7 ± 0.3**
    Compound A-1
    Administered group 1.0 718.4 ± 64.1  3.4 ± 0.3** 44.8 ± 0.4**
  • The data was shown by means±standard error of 11-12 rats per group. Each group was compared to diabetes group by Dunnett's test (**P<0.01). [0070]
  • From the above-mentioned results of Experimental Example, the compound A-1 of the present invention decreased urinary TXB2 excretion that had been increased by diabetes, and increased tail nerve conduction velocity which had been decreased by diabetes, in a dose-dependent manner without affecting the blood glucose. [0071]
    TABLE 2
    dose tail nerve conduction velocity
    test group mg/kg/day m/sec 5 wks after administration
    Control group 0 43.7 ± 0.4**
    Diabetes group 0 39.4 ± 0.2
    Compound A-2
    Administered group 0.03 40.7 ± 0.5**
    Compound A-2
    Administered group 0.1 42.6 ± 0.4**
    Compound A-2
    Administered group 0.3 43.0 ± 0.3**
    Compound A-2
    Administered group 1 42.6 ± 0.5**
  • The data was shown by mean±standard error of 10 rats per group. Each group was compared to diabetes group by Dunnett's test (**P<0.01). [0072]
    TABLE 3
    dose tail nerve conduction velocity
    test group mg/kg/day m/sec 4 wks after administration
    Control group 0 43.0 ± 0.5
    Diabetes group 0 38.8 ± 0.5
    Compound A-4
    Administered group 0.3 40.9 ± 0.5**
    Compound A-4
    Administered group 1 41.3 ± 0.4**
    Compound A-4
    Administered group 3 41.7 ± 0.5**
  • The data was shown by mean±standard error of 10 rats per group. Each group administered with the compound was compared to diabetes group by Dunnett's test (**P<0.01). [0073]
  • From the above-mentioned results of Experimental Examples, the compound A-2 and compound A4 of the present invention suppressed decrease in tail nerve conduction velocity in a dose-dependent manner. [0074]
    • Experimental Example 2
  • A 0.5% hydroxypropylmethylcellulose suspension containing the compound of the present invention was orally administered to 9-week-old male spontaneously diabetic mice (db/db) once a day. At 4-5 weeks from the administration, sciatic nerve conduction velocity was measured with an induction potential test device (neuropack 2, manufactured by Nihon Kohden) according to a modification of the method of Yasuda (Diabetes, 38, p. 832-838 (1989)). To be specific, rectal temperature was maintained at 37° C. and two points of sciatic notch and ankle were percutaneously stimulated electrically. The distance between the stimulation points was divided by the difference between latencies in induced electromyogram to give nerve conduction velocity. [0075]
    TABLE 4
    dose sciatic nerve conduction velocity
    test group mg/kg/day m/sec 4 wks after administration
    Diabetes group 0 44.3 ± 1.1
    Compound A-2
    Administered group 0.05 46.6 ± 1.5
    Compound A-2
    Administered group 0.5 51.9 ± 1.2**
    Compound A-2
    Administered group 5 51.7 ± 1.4**
  • The data was shown by mean±standard error of 7-9 mice per group. Each group was compared to diabetes group by Dunnett's test (**P<0.01). [0076]
    TABLE 5
    dose sciatic nerve conduction velocity
    test group mg/kg/day m/sec 5 wks after administration
    Diabetes group 0 39.6 ± 1.2
    Compound A-4
    Administered group 0.3 45.2 ± 1.2**
    Compound A-4
    Administered group 1 45.9 ± 0.7**
    Compound A-4
    Administered group 3 45.3 ± 0.8**
  • The data was shown by mean±standard error of 8-9 mice per group. Each group was compared to diabetes group by Dunnett's test (**P<0.01). [0077]
  • From the above-mentioned results of Experimental Examples, the compound A-2 and compound A4 of the present invention increased sciatic nerve conduction velocity of spontaneous diabetic mice. [0078]
    • Experimental Example 3
  • Diabetes was induced by intravenous administration of streptozotocin (65 mg/kg) to 6 week-old male Sprague-Dawley rats. Starting from 16 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing compound A-1 was orally administered once a day. At 5 weeks from the administration, tail nerve conduction velocity was measured with an induction potential test device (Neuropack 2, manufactured by Nihon Kohden) according to a modification of the method of Miyoshi (Fukuoka Medical Journal, vol. 62, pp. 588-603 (1971)). To be specific, subcutaneous temperature at the tail vas maintained at 37° C. and the tail nerve was percutaneously stimulated electrically at 2 stimulation points (interval 6 cm). The distance between the stimulation points was divided by the difference between latencies in induced electromyogram to give nerve conduction velocity. [0079]
    TABLE 6
    tail nerve conduction velocity (m/sec)
    dose 5 wks after
    test group mg/kg/day before administration administration
    Control group 0 54.0 ± 0.5 54.4 ± 0.5
    Diabetes group 0 46.4 ± 0.5 46.9 ± 0.3
    Compound A-1
    Administered group 0.3 46.2 ± 0.5 48.3 ± 0.6
    Compound A-1
    Administered group 1 46.1 ± 0.4 49.4 ± 0.4**
    Compound A-1
    Administered group 3 46.0 ± 0.3  502 ± 0.5**
  • The data was shown by mean±standard error of 10 rats per group. Each group administered with the compound was compared to diabetes group by Dunnett's test (**P<0.01). [0080]
  • From the above-mentioned results of Experimental Example, the compound A-1 increased tail nerve conduction velocity that had been lowered by the progression of diabetes, in a dose-dependent manner. [0081]
    • Experimental Example 4
  • Diabetes was induced by intravenous administration of streptozotocin (65 mg/k, to 5-week-old male Sprague-Dawley rats. Starting from 9 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing compound A-1 was orally administered once a day. At 9 weeks from the administration, kidney was removed to determine the degree of glomerular disorder and fixed in a 10% neutral-buffered formalin solution Tissue sections were stained with hematoxylin/eosin. Glomerulus was evaluated according to the degree of obstruction in 5 stages (0: no obstruction, 1: up to 25% obstruction, 2: up to 50% obstruction, 3: up to 75% obstruction, 4: up to 100% obstruction). Fifty glomeruli were evaluated per sample and the total score was used as an index of the degree of glomerular disorder. This operation was done under a single blind condition. [0082]
    TABLE 7
    dose
    test group mg/kg/day n glomerular disorder score
    Diabetes group 0 9 90.2 ± 7.9 
    Compound A-1
    Administered group 0.3 5 90.8 ± 10.0
    Compound A-1
    Administered group 1 7 65.7 ± 12.0
    Compound A-1
    Administered group 10 8 55.4 ± 9.2*
  • The data was shown by mean±standard error. Each group was compared to diabetes group by Dunnett's test (*P<0.05). [0083]
  • From the above-mentioned results of Experimental Example, the compound A-1 of the present invention suppressed glomerular disorder due to diabetes in a dose-dependent manner. [0084]
    • Experimental Example 5
  • Diabetes is induced by intravenous administration of streptozotocin (65 mg/kg) to 6 week old male Sprague-Dawley rats. Starting from 2 weeks after the onset of diabetes, a 0.5% hydroxypropylmethylcellulose suspension containing compound A-1 is orally administered once a day. Urine is taken with the passage of time for 24 hours at several weeks' interval. The amount of urinary albumin excretion is determined by enzyme immunoassay. In addition, retina is photographed and examined by counting neogenetic blood vessels. After the completion of the drug administration, the rats are killed and blood vessels, such as aorta, are taken to make tissue samples. The sample stained with hematoxylin/eosin is observed with an optical microscope to quantitatively determine the degree of tunica intima. [0085]
  • From the above-mentioned Formulation Examples and Pharmacological Experiments, it is clear that the pharmaceutical agent of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient. [0086]

Claims (24)

What is claimed is:
1. A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.
2. A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.
3. A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.
4. A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate.
5. A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.
6. A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.
7. A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.
8. A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate {fraction (2/3)} hydrate.
9. The method of claim 1, wherein the diabetic ophthalmopathy is cataract.
10. The method of claim 1, wherein the diabetic ophthalmopathy is glaucoma.
11. The method of claim 1, wherein the diabetic ophthalmopathy is retinopathy.
12. The method of claim 1, wherein the diabetic ophthalmopathy is iritis.
13. The method of claim 2, wherein the diabetic ophthalmopathy is cataract.
14. The method of claim 2, wherein the diabetic ophthalmopathy is glaucoma.
15. The method of claim 2, wherein the diabetic ophthalmopathy is retinopathy.
16. The method of claim 2, wherein the diabetic ophthalmopathy is iritis.
17. The method of claim 3, wherein the diabetic ophthalmopathy is cataract.
18. The method of claim 3, wherein the diabetic ophthalmopathy is glaucoma.
19. The method of claim 3, wherein the diabetic ophthalmopathy is retinopathy.
20. The method of claim 3, wherein the diabetic ophthalmopathy is iritis.
21. The method of claim 4, wherein the diabetic ophthalmopathy is cataract.
22. The method of claim 4, wherein the diabetic ophthalmopathy is glaucoma.
23. The method of claim 4, wherein the diabetic ophthalmopathy is retinopathy.
24. The method of claim 4, wherein the diabetic ophthalmopathy is iritis.
US10/784,232 1995-12-27 2004-02-24 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives Abandoned US20040171663A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/784,232 US20040171663A1 (en) 1995-12-27 2004-02-24 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US11/152,376 US20050239856A1 (en) 1995-12-27 2005-06-15 Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives
US11/363,202 US20060148875A1 (en) 1995-12-27 2006-02-28 Agent for prophylaxis and treatment of diabetic complications

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP34016195 1995-12-27
US09/091,993 US6060496A (en) 1995-12-27 1996-12-24 Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid
US09/498,481 US6258834B1 (en) 1995-12-27 2000-02-04 Method for prophylaxis and treatment of diabetic complications with 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US09/850,000 US20010036957A1 (en) 1995-12-27 2001-05-08 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/080,660 US20020169194A1 (en) 1995-12-27 2002-02-25 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/354,136 US20030130332A1 (en) 1995-12-27 2003-01-30 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/784,232 US20040171663A1 (en) 1995-12-27 2004-02-24 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
JP340161/1995 2005-12-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/354,136 Continuation US20030130332A1 (en) 1995-12-27 2003-01-30 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/152,376 Continuation US20050239856A1 (en) 1995-12-27 2005-06-15 Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives

Publications (1)

Publication Number Publication Date
US20040171663A1 true US20040171663A1 (en) 2004-09-02

Family

ID=18334321

Family Applications (8)

Application Number Title Priority Date Filing Date
US09/091,993 Expired - Lifetime US6060496A (en) 1995-12-27 1996-12-24 Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid
US09/498,481 Expired - Lifetime US6258834B1 (en) 1995-12-27 2000-02-04 Method for prophylaxis and treatment of diabetic complications with 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US09/850,000 Abandoned US20010036957A1 (en) 1995-12-27 2001-05-08 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/080,660 Abandoned US20020169194A1 (en) 1995-12-27 2002-02-25 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/354,136 Abandoned US20030130332A1 (en) 1995-12-27 2003-01-30 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/784,232 Abandoned US20040171663A1 (en) 1995-12-27 2004-02-24 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US11/152,376 Abandoned US20050239856A1 (en) 1995-12-27 2005-06-15 Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives
US11/363,202 Abandoned US20060148875A1 (en) 1995-12-27 2006-02-28 Agent for prophylaxis and treatment of diabetic complications

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US09/091,993 Expired - Lifetime US6060496A (en) 1995-12-27 1996-12-24 Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid
US09/498,481 Expired - Lifetime US6258834B1 (en) 1995-12-27 2000-02-04 Method for prophylaxis and treatment of diabetic complications with 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US09/850,000 Abandoned US20010036957A1 (en) 1995-12-27 2001-05-08 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/080,660 Abandoned US20020169194A1 (en) 1995-12-27 2002-02-25 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives
US10/354,136 Abandoned US20030130332A1 (en) 1995-12-27 2003-01-30 Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/152,376 Abandoned US20050239856A1 (en) 1995-12-27 2005-06-15 Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives
US11/363,202 Abandoned US20060148875A1 (en) 1995-12-27 2006-02-28 Agent for prophylaxis and treatment of diabetic complications

Country Status (22)

Country Link
US (8) US6060496A (en)
EP (2) EP0881218B1 (en)
JP (1) JP3448869B2 (en)
KR (2) KR100443891B1 (en)
CN (2) CN1092645C (en)
AT (1) ATE252563T1 (en)
AU (1) AU716332B2 (en)
BG (1) BG63803B1 (en)
BR (1) BR9612316A (en)
CA (1) CA2241856C (en)
CZ (1) CZ294485B6 (en)
DE (1) DE69630465T2 (en)
EE (1) EE03524B1 (en)
ES (1) ES2210399T3 (en)
HU (1) HUP0000422A3 (en)
IL (1) IL125104A (en)
IS (1) IS4784A (en)
MX (1) MX9805317A (en)
NO (1) NO316494B1 (en)
NZ (1) NZ324454A (en)
RU (1) RU2173148C2 (en)
WO (1) WO1997024333A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100443891B1 (en) * 1995-12-27 2004-10-14 미쯔비시 웰 파마 가부시키가이샤 Prevention and treatment of diabetic complications
BR0011551A (en) * 1999-05-25 2002-04-02 Mitsubishi Pharma Corp Mag expression promoters
US6482844B1 (en) * 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
WO2002041712A1 (en) * 2000-11-24 2002-05-30 Toyo Shinyaku Co., Ltd. Foods containing young wheat leaf powder
DE10229180A1 (en) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Use of vasopeptidase inhibitors in the treatment of metabolic disorders, nephropathy and AGE-associated disorders
US20040121489A1 (en) * 2002-08-29 2004-06-24 Dharnidharka Vikas R. COX-2 mediated altered prostaglandin balance in diabetes complications
GB0314945D0 (en) * 2003-06-26 2003-07-30 Black & Decker Inc Vacuum cleaner
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
RU2741715C1 (en) * 2020-03-20 2021-01-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Method for prediction of formation of microvascular complications of type 2 diabetes mellitus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448781A (en) * 1979-01-19 1984-05-15 Pfizer Inc. N-Benzyl-imidazoles as selective inhibitors of the thromboxane synthetase enzyme
US4661603A (en) * 1982-03-03 1987-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Imidazole derivatives
US4737506A (en) * 1984-08-14 1988-04-12 Kowa Co., Ltd. Anti-arteriosclerotic pyridyl or imidazolyl derivatives of carbonyloxyalkyl hantzsch esters
US4882347A (en) * 1987-06-03 1989-11-21 Farmitalia Carlo Erba, S.R.L. "N-imidazolyl derivatives of bicyclic compounds and pharmaceutical compositions containing the same"
US5091191A (en) * 1988-02-03 1992-02-25 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition with improved dissolution property
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US6060496A (en) * 1995-12-27 2000-05-09 Yoshitomi Pharmaceutical Industires, Ltd. Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277670A (en) * 1985-06-03 1986-12-08 Yoshitomi Pharmaceut Ind Ltd Imidazole derivative
JPS63119425A (en) * 1986-11-07 1988-05-24 Yoshitomi Pharmaceut Ind Ltd Immune function improving drug
JP2814513B2 (en) * 1988-02-03 1998-10-22 吉富製薬株式会社 Pharmaceutical composition with improved dissolution
JPH037281A (en) * 1989-03-31 1991-01-14 Kyoto Yakuhin Kogyo Kk Novel imidazole derivative and medical use thereof
EP0427860A1 (en) 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448781A (en) * 1979-01-19 1984-05-15 Pfizer Inc. N-Benzyl-imidazoles as selective inhibitors of the thromboxane synthetase enzyme
US4661603A (en) * 1982-03-03 1987-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Imidazole derivatives
US4737506A (en) * 1984-08-14 1988-04-12 Kowa Co., Ltd. Anti-arteriosclerotic pyridyl or imidazolyl derivatives of carbonyloxyalkyl hantzsch esters
US4882347A (en) * 1987-06-03 1989-11-21 Farmitalia Carlo Erba, S.R.L. "N-imidazolyl derivatives of bicyclic compounds and pharmaceutical compositions containing the same"
US5091191A (en) * 1988-02-03 1992-02-25 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition with improved dissolution property
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5484780A (en) * 1992-06-03 1996-01-16 Eli Lilly And Company Angiotensin II antagonists
US6060496A (en) * 1995-12-27 2000-05-09 Yoshitomi Pharmaceutical Industires, Ltd. Prophylaxis and treatment of diabetic complications with 4-[α-hydroxy-2-methyl-5-(1-imidazolyl) benzyl]-3,5-dimethylbenzoic acid
US6258834B1 (en) * 1995-12-27 2001-07-10 Welfide Corporation Method for prophylaxis and treatment of diabetic complications with 4[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives

Also Published As

Publication number Publication date
US6060496A (en) 2000-05-09
DE69630465T2 (en) 2004-07-22
US20020169194A1 (en) 2002-11-14
IL125104A0 (en) 1999-01-26
BR9612316A (en) 1999-07-13
ATE252563T1 (en) 2003-11-15
CN1092645C (en) 2002-10-16
RU2173148C2 (en) 2001-09-10
WO1997024333A1 (en) 1997-07-10
NZ324454A (en) 2000-09-29
KR19990064262A (en) 1999-07-26
BG102633A (en) 1999-09-30
CZ9802012A3 (en) 1998-12-16
EE03524B1 (en) 2001-10-15
MX9805317A (en) 1998-10-31
IL125104A (en) 2002-12-01
CA2241856A1 (en) 1997-07-10
HUP0000422A3 (en) 2001-06-28
CN1159009C (en) 2004-07-28
EP0881218B1 (en) 2003-10-22
KR100471351B1 (en) 2005-03-14
ES2210399T3 (en) 2004-07-01
CA2241856C (en) 2006-10-17
EP0881218A4 (en) 1999-01-27
KR20040045002A (en) 2004-05-31
US6258834B1 (en) 2001-07-10
AU1173597A (en) 1997-07-28
DE69630465D1 (en) 2003-11-27
EE9800208A (en) 1998-12-15
NO316494B1 (en) 2004-02-02
CZ294485B6 (en) 2005-01-12
NO982988D0 (en) 1998-06-26
US20050239856A1 (en) 2005-10-27
CN1324618A (en) 2001-12-05
IS4784A (en) 1998-06-26
CN1209122A (en) 1999-02-24
EP1394151A1 (en) 2004-03-03
US20030130332A1 (en) 2003-07-10
HUP0000422A2 (en) 2001-04-28
BG63803B1 (en) 2003-01-31
EP0881218A1 (en) 1998-12-02
NO982988L (en) 1998-08-26
KR100443891B1 (en) 2004-10-14
US20010036957A1 (en) 2001-11-01
AU716332B2 (en) 2000-02-24
US20060148875A1 (en) 2006-07-06
HK1015777A1 (en) 1999-10-22
JP3448869B2 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
US20060148875A1 (en) Agent for prophylaxis and treatment of diabetic complications
EP3338777B1 (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
EP1243261B1 (en) Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
EP0971711B1 (en) Anticancer composition comprising a diaminotrifluoromethylpyridine derivative
US8183206B2 (en) Drugs comprising combination of antithrombotic agent with pyrazolone derivative
HK1015777B (en) Preventives/remedies for complications of diabetes
JP3450399B2 (en) Angiogenesis inhibitor
CA2264101A1 (en) Preventives/remedies for muscle tissue degenerations
JP2835547B2 (en) Diabetes treatment
EP3730143A1 (en) Omidenepag combination
HK40029828A (en) Omidenepag combination
JPH06192089A (en) Inhibitor of mailard reaction
JPH10251152A (en) Medicine for treating ischemic reperfusion disorder
JP2003221334A (en) Prevention and treatment of diabetic complications
JPS58188881A (en) N-substituted imidazole derivative, manufacture and medicine
WO1993012794A1 (en) Use of an animazoline derivative for the treatment of glaucoma
SE427083B (en) Antihypertensive preparation in unit dose form, comprising, inter alia, 2-[1-(2,6-dichlorophenoxy)ethyl]- 4,5-dihydro-1H-imidazole

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION